Prelude Capital Management’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
LCM
Prelude Capital Management's STOK Position: Q3 2026 in Review
Prelude Capital Management sold out of Stoke Therapeutics (STOK) in Q3 2026, closing a stake of 7,592 shares — an estimated $248K sold.
Prelude Capital Management first reported a position in STOK in Q3 2024 and held it in 4 quarters. The position peaked at $613K in Q3 2024. 185 funds tracked by Wall St. Rank hold STOK as of Q3 2026.
- Prelude Capital Management reported no remaining Stoke Therapeutics position as of Q3 2026 after selling out during the quarter.
- Prelude Capital Management sold 7,592 Stoke Therapeutics shares in Q3 2026, an estimated $248K.
- Prelude Capital Management first reported a position in Stoke Therapeutics in Q3 2024 and held it in 4 quarters.
- Prelude Capital Management's Stoke Therapeutics position peaked at $613K in Q3 2024.
- 185 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.
Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.